Lilly UK is one of the largest providers of medicines to the UK National Health Service. Lilly´s medicines are currently treating schizophrenia, diabetes, bipolar disorder, stress urinary incontinence, erectile dysfunction, depression, cancer, heart disease, pain, infections and gastric disorders across the UK and bringing relief to millions of people.
Headquartered in Basingstoke, Hampshire with employees throughout England, Scotland, Wales and Northern Ireland the company is committed to creating value adding relationships throughout the NHS. This relationship is not simply about selling medicines it is all about adding value to the health care delivery process for the optimum benefit of the patient and the health care professional.
Lilly´s continuing success is based upon working in partnership with health care professionals, listening to patients and responding quickly to changing circumstances. The company believes that the prevention and treatment of disease is about much more than providing effective medicines. That is why Lilly takes a lead in providing a wide range of support services such as health outcome data, specialist product services, information packs, and non product related services such as business management training.
The National Health Service is constantly changing and Lilly has been at the forefront of adapting to its changing customer´s needs. The company works closely with NHS managers on best practice in health management, optimising health outcomes and assisting in effective clinical management to ensure that the best possible value can be derived from the company´s medicines.
Discovering and delivering innovative ground breaking medicines to the patient is an expensive and lengthy process - more than £300 million and 10 years for each new medicine. However modern medicines often reduce the cost of disease to society as a whole. The introduction of anti-ulcer drugs in the ´eighties almost totally eradicated the need for expensive surgery. The advent of effective medicines for HIV has meant the closure of hospital wards and subsequent economic savings. Of course Lilly does not believe such claims should be taken at face value and invests in health economic evaluative research to demonstrate the true value of its innovative medicines.
|
About
